191 related articles for article (PubMed ID: 8371133)
1. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
2. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
Labbé L; Abolfathi Z; Robitaille NM; St-Maurice F; Gilbert M; Turgeon J
Ther Drug Monit; 1999 Apr; 21(2):191-9. PubMed ID: 10217339
[TBL] [Abstract][Full Text] [Related]
4. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
5. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
7. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
8. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
9. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
Paczkowski D; Sadowski Z; Filipek M; Koliński P
Pol J Pharmacol Pharm; 1990; 42(4):365-75. PubMed ID: 2097598
[TBL] [Abstract][Full Text] [Related]
13. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
16. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
18. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
Sowinski KM; Burlew BS
Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]